Cue Biopharma, Inc. (CUE): Entry into a Material Definitive Agreement
Cue Biopharma, Inc. (CUE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 d123955dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “ Agreement ”) is dated as of July 9, 2026, by and among Cue Biopharma, Inc., a Delaware corporation (the “ Company ”), and each of the purchasers liste
How this was made
The 30-second read
Why it matters
The key tradable implication is capital structure change from an equity issuance package. Pre-funded warrants typically reduce investor downside while capping ownership via a beneficial ownership limitation (19.9%). Registration rights can affect future selling pressure and liquidity.
Market read
This is a primary-source financing disclosure that can drive immediate repricing due to dilution risk and warrant economics, even without clinical or operational updates in the excerpt.
What to watch
Traders will want the missing deal economics (total shares, gross proceeds, closing date, investor identities, and any use-of-proceeds) to judge whether dilution is manageable versus value-destructive.
Background
The 8-K references a July 9, 2026 securities purchase agreement with investors for common stock and pre-funded warrants, plus a contemporaneous registration rights agreement.
Ticker impact
Cue Biopharma filed an 8-K for a securities purchase agreement, selling common stock and pre-funded warrants with registration rights.
Near-term downside or volatility risk from dilution; direction depends on deal size and pricing, which are not included in the provided excerpt.
This is a primary SEC disclosure of a material definitive agreement for an unregistered equity sale. The excerpt confirms the instrument types and a pre-funded warrant price ($33.209) but does not provide gross proceeds, share count, or closing terms, limiting precision on magnitude.
Market effects
Adds to the ongoing pattern of biotech financing via common stock plus pre-funded warrants, which can influence sentiment around small-cap capital needs.
Primarily impacts US-listed small-cap biotech risk appetite.
Limited, as the disclosure is company-specific and US securities-law driven.
Counterpoint
If the financing price and terms are favorable and proceeds fund near-term catalysts, the market may interpret the deal as runway extension rather than purely dilution.
Key entities
- issuerCue Biopharma, Inc.
Company entering a material definitive securities purchase agreement and related registration rights.
- counterpartiesInvestors (Exhibit A)
Purchasers of common stock and pre-funded warrants under the unregistered Reg D exemption.
